Welcome to CSNpharm! For Research Use Only!
ERK
| Cat. No. | Product Name | CAS No. | Information |
|---|---|---|---|
| CSN16763 | XMD8-92 | 1234480-50-2 | XMD8-92 is an inhibitor of ERK5BMK1 The Kd values for BMK1 DCAMKL2 PLK4 and TNK1 are 80 nM 190 nM 600 nM and 890 nM respectively |
| CSN17855 | XMD17-109 | 1435488-37-1 | XMD17-109 is a specific ERK-5 inhibitor with an EC50 42 M in HEK293 cells |
| CSN18540 | VX-11e | 896720-20-0 | VX-11e is a potent, selective, and orally bioavailable inhibitor of ERK (Extracellular Signal-Regulated Kinase) and is antitumor agent. |
| CSN15784 | Ulixertinib | 869886-67-9 | Ulixertinib is a potent and reversible ERK1ERK2 inhibitor with IC50 of 0.3 nM for ERK2. |
| CSN23392 | Ulixertinib hydrochloride | 1956366-10-1 | Ulixertinib HCl the salt of ulixertinib is a reversible inhibitor of ERK1ERK2 It can inhibit cell proliferation |
| CSN25710 | TMCB | 905105-89-7 | TMCB is a dual-kinase inhibitor of both casein kinase 2 (CK2) and extracellular-signal-regulated kinase 8 (ERK8) with IC50s of 0.50 μM. |
| CSN13643 | SCH772984 | 942183-80-4 | SCH772984 is a specific inhibitor of ERK12 with IC50 of 4 nM and 1 nM respectively |
| CSN33183 | Rineterkib | 1715025-32-3 | Rineterkib is a RAF and ERK1/2 inhibitor which has demonstrated preclinical activity in multiple MAPK activated cancer cells and xenograft models. |
| CSN33184 | Rineterkib hydrochloride | 1715025-34-5 | Rineterkib is a RAF and ERK1/2 inhibitor which has demonstrated preclinical activity in multiple MAPK activated cancer cells and xenograft models. |
| CSN17141 | Pluripotin | 839707-37-8 | Pluripotin is a dual inhibitor of extracellular signal-regulated kinase 1 ERK1 MAPK3 and RasGAP It maintains embryonic stem cell ESC self-renewal |
| CSN26520 | Mps1-IN-1 dihydrochloride | 1883548-93-3 | Mps1-IN-1 dihydrochloride is a potent, selective and ATP-competitive Mps1 kinase inhibitor, with an IC50 and a Kd of 367 nM and 27 nM[1]. |
| CSN21082 | MK-8353 | 1184173-73-6 | MK-8353 also known as SCH900353 is a potent and orally active ERK12 inhibitor and anticancer drug candidate currently being developed by Schering-Plough MK-8353 exhibited comparable potency with SCH772984 across various preclinical cancer models |
| CSN11353 | Magnolin | 31008-18-1 | Magnolin, a natural product isolated and purified from the flowers of Magnolia biondii Pamp., reduces the renal oxidative stress, suppresses caspase-3 activity, and increases Bcl-2 expression in vivo and in vitro. |
| CSN20623 | Temuterkib | 1951483-29-6 | LY3214996 can inhibit ERK1 and ERK2 with IC50s of 5 nM |
| CSN24745 | Longdaysin | 1353867-91-0 | Longdaysin inhibited CKIδ, CKIα, ERK2 and CDK7 with IC50 values of 8.8, 5.6, 52, and 29μM, respectively. The EC50 values of longdaysin for CKIδ and CKIα in the cell-based PER1 degradation assay were 9.7 and 9.2μM, respectively. |
| CSN22441 | KO-947 | 1695533-89-1 | KO-947 is a potent and selective inhibitor of ERK12 kinases with potential clinical utility in MAPK pathway dysregulated tumors |
| CSN14412 | Hirsutenone | 41137-87-5 | Hirsutenone, a natural product isolated and purified from the eaves of Alnus nepalensis, exhibits anti-cancer effect against prostate cancer through a direct physical inhibition of Akt1/2, attenuates adipogenesis by directly targeting PI3K and ERK during MCE in 3T3-L1 preadipocytes, underscoring the potential therapeutic application of Hirsutenone in preventing obesity, and may exert a preventive effect against microbial endotoxin lipopolysaccharide-induced inflammatory skin diseases through inhibition of ERK pathway-mediated NF-kappaB activation. Hirsutenone showed potent PL(pro) inhibitory activity with IC50 value of 4.1µM. |
| CSN16271 | Ravoxertinib | 1453848-26-4 | GDC-0994 is a selective inhibitor of ERK1/2 with IC50 value of 6.1 nM and 3.1 nM. |
| CSN19017 | Ravoxertinib hydrochloride | 2070009-58-2 | GDC-0994 hydrochloride is highly selective for ERK1 and ERK2 with biochemical potency of 11 nM and 03 nM respectively |
| CSN13064 | FR 180204 | 865362-74-9 | FR 180204 is a potent and selective ATP-competitive inhibitor of ERK1 and ERK2 with Ki value of 031 M and 014 M respectively and has IC50 values of 051 and 033 M in enzymatic assays against ERK1 and ERK2 respectively |
| CSN26645 | SKI V | 24418-86-8 | for hPI3k. SKI V decreases formation of the mitogenic second messenger sphingosine-1-phosphate (S1P). SKI V induces apoptosis and has antitumor activity[1][2]. |
| CSN24288 | ERK5-IN-2 | 1888305-96-1 | ERK5-IN-2 is a selective ERK5 inhibitor with IC50 value of 0.82 μM. |
| CSN17601 | ERK5-IN-1 | 1234479-76-5 | ERK5-IN-1 exhibits potent inhibition of ERK5 with cellular EC50 values of 019 M and enzymatic IC50 values of 0087 M and of LRRK2G2019S with enzymatic IC50 values of 0026M |
| CSN18045 | DEL-22379 | 181223-80-3 | DEL-22379 inhibits ERK dimerization with IC50 of 05 M |
| CSN22365 | CC-90003 | 1621999-82-3 | CC-90003 is an irreversible inhibitor of ERK 12 with antitumor activity |
| CSN24804 | BCI-215 | 1245792-67-9 | BCI-215 is a hyperactivator of fibroblast growth factor signaling that is devoid of developmental toxicity and restores defective MAPK activity caused by overexpression of DUSP1 and DUSP6 in mammalian cells. BCI-215 induced rapid and sustained phosphorylation of extracellular signal-regulated kinase (ERK), p38, and c-Jun N-terminal kinase (JNK) in the absence of reactive oxygen species, and its toxicity was partially rescued by inhibition of p38 but not JNK or ERK. |
| CSN27196 | BAY885 | 2307249-33-6 | BAY-885 is a highly potent and selective ERK5 inhibitor with IC50 value of 35nM. |
| CSN21094 | Tizaterkib | 2097416-76-5 | AZD0364 is an ERK1 andor ERK2 kinase for the treatment of cancer |
| CSN22695 | AX-15836 | 2035509-96-5 | AX 15836 is a potent and selective ERK5 inhibitor with IC50 of 8 nM. |
| CSN27671 | ASTX029 | 2095719-92-7 | ASTX-029 is selective inhibitor of the extracellular signal-regulated kinases 1 and 2 (ERK 1/2) with potential antineoplastic activity. |
| CSN19016 | APS-2-79 | 2002381-25-9 | APS-2-79 is an antagonist of MEK phosphorylation by RAF through direct binding of the KSR active site |
| CSN21221 | AG126 | 118409-62-4 | AG 126 selectively inhibits the phosphorylation of ERK1 and ERK2 at 25-50 M. |
| CSN68211 | GSK143 | 1240390-27-5 |
+1-708-781-1677
+1-708-286-6026
sales@csnpharm.com
